US Patent 10,695,397: Scope, Claims, Expiration, and Patent Landscape for Oral Octreotide in Acromegaly

US Patent No. 10,695,397 protects a narrow treatment protocol for oral octreotide in acromegaly. Its core requirements are: prior effective and tolerated treatment with a somatostatin analog, oral administration of 20-mg octreotide dosage forms twice daily, administration in a fasting window, and a total daily dose of 40, 60, or 80 mg. The patent does not broadly claim octreotide, oral octreotide, or every formulation of oral octreotide.

The patent is associated with Mycapssa, the delayed-release oral octreotide capsule developed by Chiasma and approved by the FDA in 2020. Mycapssa received orphan-drug exclusivity through June 2027, while the relevant patent protection extends into the 2030s, subject to the official patent-term calculation and any applicable patent-term adjustment or extension.[1][2]

What does US Patent 10,695,397 protect?

The patent protects a method of treating acromegaly using specific oral octreotide dosing conditions. Claim 1 is the central independent claim.

Claim element	Requirement
Disease	Acromegaly
Patient history	Prior treatment with somatostatin analogs was effective and tolerated
Route	Oral
Dosage form	At least one dosage form containing octreotide
Strength	20 mg octreotide per dosage form
Frequency	Twice daily
Food restriction	At least one hour before a meal or at least two hours after a meal
Total daily dose	40 mg, 60 mg, or 80 mg
Treatment result	Treatment of acromegaly

Every limitation in claim 1 must be present for literal infringement. A product or treatment regimen that omits one required limitation may avoid literal infringement, although inducement, contributory infringement, doctrine-of-equivalents, and claim-construction issues could still arise in litigation.

How narrow is the scope of claim 1?

Claim 1 is narrower than a general claim to oral octreotide for acromegaly. It requires the combination of:

A patient previously responsive to and tolerant of somatostatin analog therapy.
A 20-mg dosage form.
Twice-daily oral administration.
Administration under a specified fasting condition.
A total dose of 40, 60, or 80 mg per day.

The prior-response requirement is particularly important. A regimen used in a patient who has never received a somatostatin analog, or in a patient whose prior somatostatin analog treatment was ineffective or not tolerated, may fall outside the literal scope of claim 1.

The claim also does not cover every dosing schedule. A 10-mg capsule given twice daily, a 40-mg capsule given once daily, or an injectable octreotide regimen would not satisfy the express 20-mg-per-dosage-form and twice-daily limitations.

What do claims 2 through 11 cover?

Claims 2 through 11 narrow the delivery format and daily administration schedule.

Claim	Subject matter
2	Oily suspension formulated into a capsule
3	Morning and evening administration
4	Enteric coating on the capsule
5	One or two dosage forms at each administration
6	One dosage form in the morning and one in the evening
7	Two dosage forms at the first administration and one at the second
8	Two dosage forms at both administrations
9	One dosage form administered twice daily
10	Two dosage forms administered twice daily
11	One dosage form at one daily administration and two at another

Claims 6, 7, 8, 9, and 10 map directly onto the 40-mg, 60-mg, and 80-mg dosing options:

40 mg daily: one 20-mg capsule in the morning and one in the evening.
60 mg daily: two capsules at one administration and one at the other.
80 mg daily: two capsules in the morning and two in the evening.

Claim 4 adds an enteric coating limitation. A capsule containing an oily octreotide suspension but lacking an enteric coating may fall outside claim 4 while potentially remaining within claim 2 or claim 1.

The formulation language does not create a stand-alone composition claim. These are method claims. The capsule, oily suspension, and enteric coating are protected only when used in the claimed treatment method.

What dosing algorithm is protected by claims 12 through 15?

Claims 12 through 15 cover dose titration based on IGF-1 levels, clinical symptoms, and maintained biochemical or symptomatic response.

Starting dose	Patient response	Claimed action
40 mg daily, given as 20 mg twice daily	IGF-1 normal and symptoms controlled	Continue 40 mg daily
40 mg daily	IGF-1 not normal and symptoms not controlled	Increase to 60 mg daily
60 mg daily, given as 40 mg morning and 20 mg evening	Response maintained	Continue 60 mg daily
60 mg daily	Response not maintained	Increase to 80 mg daily
80 mg daily, given as 40 mg morning and 40 mg evening	Covered by the preceding regimen structure	Maintain the claimed maximum dose under claim 1

These claims may be relevant to a product label that directs physicians to begin at 40 mg daily and escalate based on IGF-1 and symptom control. A generic applicant that copies the same titration instructions may face method-of-use infringement exposure even if the generic product itself is not structurally covered.

Claims 12 through 15 use alternative response concepts, including normal IGF-1, controlled clinical symptoms, and maintained biochemical or symptomatic response. Claim construction could determine whether these are separate alternatives or cumulative requirements in a particular infringement dispute.

What is the likely patent expiration date for US 10,695,397?

US Patent 10,695,397 was issued on June 30, 2020. Its term is expected to extend into 2033 based on the underlying US application and international filing history. The precise expiration date should be taken from the USPTO patent-term calculation and any FDA Orange Book listing.

Milestone	Date or status
Patent	US 10,695,397
Issue date	June 30, 2020
Patent type	Utility patent
Core technology	Oral octreotide treatment method
Expected statutory term	Into 2033
FDA approval of Mycapssa	June 26, 2020
Orphan-drug exclusivity	Generally through June 26, 2027
Generic pathway after patent and exclusivity barriers	ANDA, subject to listed patents and certifications

The patent term is separate from FDA regulatory exclusivity. Orphan-drug exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity period, subject to statutory exceptions. It does not extend the patent term.[2]

What is the Orange Book status of Mycapssa and US 10,695,397?

Mycapssa is an FDA-approved oral octreotide product indicated for maintenance treatment in adults who have responded to and tolerated treatment with octreotide or lanreotide.[2] That indication corresponds closely to the prior-treatment limitation in claim 1.

US 10,695,397 is the principal method-of-use patent associated with the claimed oral octreotide treatment protocol. The relevant Orange Book analysis should distinguish:

Patent listings for the approved use.
Any separate formulation or drug-product patents.
Any patent-term adjustment.
Any later-issued continuation or divisional patents.
The expiration date reported in the current FDA publication.

The FDA label is commercially important because it can create induced-infringement risk. A generic label that directs use for the protected acromegaly indication, specifies the patented dose schedule, and reproduces the fasting instructions may expose the applicant to a method-of-use claim even if the applicant files a Paragraph IV certification against the patent.[3]

What Paragraph IV challenges and generic-entry risks exist?

Octreotide is a small molecule, so a follow-on applicant would generally use the ANDA pathway rather than the biosimilar pathway. The applicant could certify under Paragraph IV that a listed patent is invalid, unenforceable, or will not be infringed, or could submit a section viii statement carving out a patented use from its label.[4]

Paragraph IV risk

A Paragraph IV challenge to US 10,695,397 would likely focus on:

Obviousness of the 20-mg twice-daily regimen.
Obviousness of fasting administration.
Whether prior somatostatin analog response and tolerance are limiting claim elements.
Written-description and enablement support for the 40-, 60-, and 80-mg dosing range.
The patentability of the dose-escalation algorithm.
Anticipation by clinical protocols, publications, or prior patent filings.

The fasting limitation may provide a meaningful defense for an applicant whose proposed label omits the claimed food instructions. The prior-response limitation could also narrow the relevant patient population.

Section viii risk

A section viii carve-out could be commercially difficult if the approved product’s principal indication and label instructions are closely aligned with the patented method. A generic applicant would need to remove the protected use without removing noninfringing uses or creating an inadequate label under FDA requirements.

Likely launch scenarios

Scenario	Commercial result
Patent upheld and label retains the protected method	Launch generally delayed until patent expiry or settlement date
Patent invalidated in litigation	Earlier launch possible, subject to other patents and exclusivity
Label successfully carved out	Narrower generic launch possible
Settlement with licensed entry	Entry date depends on negotiated terms
Patent not asserted after Paragraph IV notice	Entry may proceed after applicable litigation timing
Orphan exclusivity remains active	FDA approval for the same protected indication may remain blocked through June 2027

No biologic interchangeability or biosimilar pathway is implicated. The main competitive issue is an ANDA challenge to a small-molecule oral formulation and its associated method-of-use patents.

Does US 10,695,397 cover the Mycapssa capsule itself?

Not broadly. The patent does not claim every capsule containing octreotide. Claims 2 and 4 require an oily suspension and, for claim 4, an enteric coating, but those limitations appear in a method-of-treatment context.

A competing product could potentially avoid the patent by using:

A different octreotide strength.
A non-enteric oral formulation.
A different release mechanism.
A different dosing frequency.
A different dosing schedule.
A label that excludes the patented acromegaly method.

That analysis would not eliminate risk under other patents covering formulation architecture, excipients, manufacturing processes, or oral absorption technology.

How does this patent compare with formulation and manufacturing protection?

US 10,695,397 is strongest as a regimen patent. It is less comprehensive as a product or manufacturing patent because the supplied claims do not cover:

The octreotide molecule itself.
A composition independent of patient treatment.
A capsule independent of its use.
A manufacturing process.
A particular excipient system in all uses.
A broad pharmacokinetic profile.
Every oral dosage form.

The commercial barrier therefore depends on the combined patent estate, not this patent alone. A generic manufacturer could face separate patents covering the oral delivery platform, enteric protection, oily suspension, capsule construction, or manufacturing process.

What patent litigation affects Mycapssa and oral octreotide?

US 10,695,397 creates the most direct litigation risk around an ANDA label that copies the Mycapssa indication and dosing instructions. The principal dispute would likely be a Hatch-Waxman patent case under 35 U.S.C. § 271(e)(2), triggered by a Paragraph IV filing.

The patent’s litigation strengths are:

Clear alignment between the approved Mycapssa indication and claim 1.
Specific dose strengths and dosing schedules.
Objective fasting instructions.
Dependent claims directed to the 40-, 60-, and 80-mg regimens.
A dose-titration pathway tied to IGF-1 and symptom control.

Potential weaknesses include:

The narrow patient-history limitation.
Possible prior art involving oral octreotide and acromegaly maintenance therapy.
Potential obviousness arguments based on conventional twice-daily dosing and dose escalation.
The absence of a broad composition claim in the supplied claims.

No settlement agreement or publicly established Paragraph IV judgment is identified here for this patent. Patent litigation status can change through new ANDA filings, district court complaints, settlements, or Federal Circuit decisions.

Which companies compete with Mycapssa?

Mycapssa competes primarily with injectable somatostatin analog products rather than with another approved oral octreotide product.

Product or class	Company examples	Route	Competitive relevance
Mycapssa	Chiasma/Amryt, with later commercial ownership relationships involving Chiesi	Oral capsule	Direct product associated with US 10,695,397
Sandostatin LAR	Novartis	Long-acting injectable	Established acromegaly maintenance therapy
Somatuline Depot	Ipsen	Long-acting injectable	Major injectable competitor
Generic octreotide injection	Multiple manufacturers	Injectable	Price competition, but not a direct oral substitute
Pegvisomant	Pfizer/Somavert historically	Injectable growth-hormone receptor antagonist	Different mechanism and administration

The key commercial value of Mycapssa is the oral route for patients who are otherwise maintained on injectable somatostatin analog therapy. The patent claim tracks that switching population by requiring prior effective and tolerated somatostatin analog treatment.

What revenue exposure does the patent create?

The patent is most relevant to revenue generated from adult acromegaly patients who:

Respond to injectable octreotide or lanreotide.
Tolerate that therapy.
Transition to oral octreotide.
Use 20-mg capsules twice daily or an escalated 60- or 80-mg daily regimen.
Follow the fasting administration instructions.

Generic entry would likely affect the entire labeled market if a generic applicant obtained approval for the same indication. The economic impact would depend on whether the generic could launch with a carved-out label, whether other patents remain in force, and whether the generic challenges the patent before 2033.

Orphan-drug exclusivity provides a regulatory barrier through 2027, but it does not prevent off-label use of an unapproved product in the same patient population after generic approval for a different indication. The patent remains more important for the labeled acromegaly market after the orphan-exclusivity period ends.

Key Takeaways

US 10,695,397 is a narrow method-of-treatment patent for oral octreotide in acromegaly.
Claim 1 requires prior effective and tolerated somatostatin analog treatment, 20-mg dosage forms, twice-daily dosing, fasting administration, and a 40-, 60-, or 80-mg total daily dose.
Claims 2 and 4 narrow the formulation to an oily suspension in a capsule and, for claim 4, an enteric-coated capsule.
Claims 12 through 15 protect dose adjustment based on IGF-1 and clinical response.
The patent does not broadly claim octreotide, every oral capsule, or an independent composition.
Mycapssa was FDA-approved on June 26, 2020, with orphan-drug exclusivity generally extending through June 2027.
Patent protection is expected to extend into 2033, subject to the official USPTO and FDA term calculations.
A generic applicant would likely use an ANDA and could pursue Paragraph IV or a section viii label carve-out.
The principal infringement risk concerns a generic label that reproduces the protected acromegaly indication, fasting instructions, and 40-, 60-, or 80-mg dosing protocol.
Biosimilar risk is not applicable because octreotide is a small molecule.

FAQs About US Patent 10,695,397 and Mycapssa

Can a generic use a different octreotide capsule strength?

Potentially. A capsule strength other than 20 mg would not literally satisfy the central dosage-form limitation in claim 1, although other patents and infringement theories could remain relevant.

Does the patent cover once-daily oral octreotide?

The supplied independent claim requires twice-daily administration. Claims 9 and 10 also expressly concern once-daily administration of one or two dosage forms at each administration, but the claim set must be construed as a whole to determine the precise schedule covered by claim 11.

Is Mycapssa protected by orphan-drug exclusivity or patents?

Both. FDA orphan-drug exclusivity is a regulatory protection, generally through June 2027. US 10,695,397 is a patent-based protection expected to extend into the 2030s.[1][2]

Could a generic launch before patent expiry with a skinny label?

Possibly, if the applicant successfully removes the protected method from its labeling and avoids inducing use of the patented regimen. FDA approval, patent litigation, other listed patents, and the adequacy of the carve-out would control the outcome.

Is an oral octreotide product a biosimilar?

No. Octreotide is a synthetic small-molecule peptide drug. A follow-on product would generally use the ANDA pathway rather than the 351(k) biosimilar pathway.

References

United States Patent and Trademark Office. (2020). US Patent No. 10,695,397, Methods of treating acromegaly.
U.S. Food and Drug Administration. (2020). Mycapssa prescribing information. Chiasma, Inc.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	10,695,397	⤷ Start Trial				USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016215350	⤷ Start Trial
Australia	2022201269	⤷ Start Trial
Australia	2024203939	⤷ Start Trial
Canada	2975599	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,695,397

Which drugs does patent 10,695,397 protect, and when does it expire?

Summary for Patent: 10,695,397